Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dronabinol for Agitation in Dementia
NCT05612711Phase 2Withdrawn
- Sponsor
- Ralph H. Johnson VA Medical Center
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in agitation comparing Dronabinol First with Placebo First (2 arms). Primary endpoints: Cohen Mansfield Agitation Inventory at 18 weeks and Treatment Emergent Adverse Events at 18 weeks. Planned start Nov 2023; status: withdrawn.
02
Drugs
dronabinol
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05612711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612711.